Tactile Medical Receives PDAC Approval For Nimbl Lymphedema Platform
Portfolio Pulse from Benzinga Newsdesk
Tactile Systems Technology, Inc. (NASDAQ:TCMD) has received PDAC approval for its Nimbl Lymphedema Platform, allowing it to be billed under HCPCS code E0651. This follows FDA clearance in June 2024, with commercial availability in the U.S. expected soon.
September 16, 2024 | 12:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Tactile Systems Technology has received PDAC approval for its Nimbl Lymphedema Platform, allowing it to be billed under HCPCS code E0651. This regulatory milestone follows FDA clearance and paves the way for U.S. commercial availability.
The PDAC approval for the Nimbl platform is a significant regulatory milestone, allowing Tactile Medical to bill Medicare, which could lead to increased sales and revenue. The upcoming U.S. commercial launch further supports a positive short-term impact on TCMD's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100